Login to Your Account

InSite Shares Gain on BromSite Phase III Data

By Marie Powers
Staff Writer

Wednesday, March 20, 2013
Investors took notice as InSite Vision Inc. reported positive top-line findings from its first Phase III trial of BromSite (ISV-303) for the reduction of inflammation and pain following cataract surgery. The company said BromSite, which combines a low dose (0.075 percent) of the nonsteroidal anti-inflammatory (NSAID) bromfenac with InSite's DuraSite drug delivery technology, achieved statistically significant superiority compared to vehicle.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription